AR101806A1 - Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio - Google Patents
Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominioInfo
- Publication number
- AR101806A1 AR101806A1 ARP150102888A ARP150102888A AR101806A1 AR 101806 A1 AR101806 A1 AR 101806A1 AR P150102888 A ARP150102888 A AR P150102888A AR P150102888 A ARP150102888 A AR P150102888A AR 101806 A1 AR101806 A1 AR 101806A1
- Authority
- AR
- Argentina
- Prior art keywords
- tetrahydroquinoline
- acetyl
- amino
- carboxamide
- dimethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia de afecciones para las cuales está indicado un inhibidor de bromodominio. Reivindicación 1: Un compuesto seleccionado del grupo que consiste en: 1-acetil-4-((5-cloropirimidin-2-il)amino)-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-2,3-dimetil-N-(tetrahidro-2H-piran-4-il)-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-((R)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-((S)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-2,3-dimetil-N-(tetrahidro-2H-piran-4-il)-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-((S)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-((R)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopirazin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopirazin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-N-etil-4-((5-fluoropiridin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-etil-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; y@@@1-acetil-4-((5-cianopiridin-2-il)amino)-N-etil-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049449P | 2014-09-12 | 2014-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101806A1 true AR101806A1 (es) | 2017-01-11 |
Family
ID=54065889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102888A AR101806A1 (es) | 2014-09-12 | 2015-09-10 | Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US10059699B2 (es) |
| EP (1) | EP3191476B1 (es) |
| JP (1) | JP6531167B2 (es) |
| KR (1) | KR20170054421A (es) |
| CN (1) | CN106687453B (es) |
| AR (1) | AR101806A1 (es) |
| AU (1) | AU2015314184B2 (es) |
| BR (1) | BR112017004580A2 (es) |
| CA (1) | CA2958159A1 (es) |
| CL (1) | CL2017000587A1 (es) |
| CO (1) | CO2017001601A2 (es) |
| CR (1) | CR20170090A (es) |
| CY (1) | CY1121369T1 (es) |
| DK (1) | DK3191476T3 (es) |
| DO (1) | DOP2017000058A (es) |
| EA (1) | EA031679B9 (es) |
| ES (1) | ES2705623T3 (es) |
| HR (1) | HRP20182064T1 (es) |
| HU (1) | HUE041694T2 (es) |
| IL (1) | IL250397A0 (es) |
| LT (1) | LT3191476T (es) |
| MA (1) | MA40366A (es) |
| MX (1) | MX2017003219A (es) |
| PE (1) | PE20170675A1 (es) |
| PH (1) | PH12017500348A1 (es) |
| PL (1) | PL3191476T3 (es) |
| PT (1) | PT3191476T (es) |
| RS (1) | RS58135B1 (es) |
| SG (1) | SG11201701043UA (es) |
| SI (1) | SI3191476T1 (es) |
| TR (1) | TR201820050T4 (es) |
| TW (1) | TWI686389B (es) |
| UY (1) | UY36292A (es) |
| WO (1) | WO2016038120A1 (es) |
| ZA (1) | ZA201700883B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE053431T2 (hu) | 2013-03-14 | 2021-07-28 | Boehringer Ingelheim Int | Szubsztituált 2-aza-biciklo[2.2.1]heptán-3-karbonsav-(benzil-ciano-metil)-amidok, mint a katepszin-C inhibitorai |
| UA118610C2 (uk) | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
| US11028051B2 (en) * | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| US11192900B2 (en) | 2018-10-30 | 2021-12-07 | Nuvation Bio Inc. | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors |
| JP7465945B2 (ja) | 2019-07-02 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | Ｂｅｔ阻害剤としてのヘテロ環式化合物 |
| EP4095128A1 (en) | 2021-05-25 | 2022-11-30 | Centre national de la recherche scientifique | Tetrahydroquinoline (thq) coumpounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791090B2 (en) * | 2009-03-31 | 2014-07-29 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| KR101780784B1 (ko) * | 2013-03-14 | 2017-09-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 2,3-이치환된 1-아실-4-아미노-1,2,3,4-테트라하이드로퀴놀린 유도체 및 이의 브로모도메인 억제제로서의 용도 |
-
2015
- 2015-09-09 JP JP2017513723A patent/JP6531167B2/ja not_active Expired - Fee Related
- 2015-09-09 DK DK15760461.2T patent/DK3191476T3/en active
- 2015-09-09 HU HUE15760461A patent/HUE041694T2/hu unknown
- 2015-09-09 EA EA201790484A patent/EA031679B9/ru not_active IP Right Cessation
- 2015-09-09 RS RS20190001A patent/RS58135B1/sr unknown
- 2015-09-09 SG SG11201701043UA patent/SG11201701043UA/en unknown
- 2015-09-09 ES ES15760461T patent/ES2705623T3/es active Active
- 2015-09-09 US US15/509,894 patent/US10059699B2/en active Active
- 2015-09-09 PL PL15760461T patent/PL3191476T3/pl unknown
- 2015-09-09 BR BR112017004580-0A patent/BR112017004580A2/pt not_active Application Discontinuation
- 2015-09-09 LT LTEP15760461.2T patent/LT3191476T/lt unknown
- 2015-09-09 SI SI201530529T patent/SI3191476T1/sl unknown
- 2015-09-09 AU AU2015314184A patent/AU2015314184B2/en not_active Ceased
- 2015-09-09 MA MA040366A patent/MA40366A/fr unknown
- 2015-09-09 CR CR20170090A patent/CR20170090A/es unknown
- 2015-09-09 PT PT15760461T patent/PT3191476T/pt unknown
- 2015-09-09 EP EP15760461.2A patent/EP3191476B1/en active Active
- 2015-09-09 KR KR1020177008675A patent/KR20170054421A/ko unknown
- 2015-09-09 TR TR2018/20050T patent/TR201820050T4/tr unknown
- 2015-09-09 PE PE2017000388A patent/PE20170675A1/es unknown
- 2015-09-09 CN CN201580048713.8A patent/CN106687453B/zh not_active Expired - Fee Related
- 2015-09-09 CA CA2958159A patent/CA2958159A1/en not_active Abandoned
- 2015-09-09 MX MX2017003219A patent/MX2017003219A/es active IP Right Grant
- 2015-09-09 WO PCT/EP2015/070665 patent/WO2016038120A1/en active Application Filing
- 2015-09-10 UY UY0001036292A patent/UY36292A/es not_active Application Discontinuation
- 2015-09-10 AR ARP150102888A patent/AR101806A1/es unknown
- 2015-09-10 TW TW104129977A patent/TWI686389B/zh not_active IP Right Cessation
-
2017
- 2017-02-01 IL IL250397A patent/IL250397A0/en unknown
- 2017-02-03 ZA ZA2017/00883A patent/ZA201700883B/en unknown
- 2017-02-17 CO CONC2017/0001601A patent/CO2017001601A2/es unknown
- 2017-02-27 PH PH12017500348A patent/PH12017500348A1/en unknown
- 2017-03-07 DO DO2017000058A patent/DOP2017000058A/es unknown
- 2017-03-09 CL CL2017000587A patent/CL2017000587A1/es unknown
-
2018
- 2018-12-06 HR HRP20182064TT patent/HRP20182064T1/hr unknown
-
2019
- 2019-01-15 CY CY20191100049T patent/CY1121369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR101806A1 (es) | Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| UY36342A (es) | Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| TR201900659T4 (tr) | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |